SAN DIEGO--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), Israel’s leading drug development company, reported today data from its Phase I trial of BL-1020, the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. The trial demonstrated that the compound was well tolerated and demonstrated biochemical evidence of dopamine blockade which is indicative of efficacy. BioLineRx presented the data in a poster (Abstract 235 XX) at the 2007 American Psychiatric Association (APA) Annual Meeting, which is being held May 19-24 in San-Diego, CA. A Phase II clinical trial for BL-1020 to determine the maximum tolerated dose in schizophrenic patients is expected to begin in the end of June, 2007.
